Showing 1 - 3 results of 3 for search 'Simon Rückinger', query time: 0.03s Refine Results
  1. 1
    Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patients

    Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and antidrug antibodies in PANAMO: a phase 3 study in critically ill,  invasively mechanically ventilated COVID-19 patien... by Endry H. T. Lim, Alexander P. J. Vlaar, Sanne de Bruin, Simon Rückinger, Claus Thielert, Maria Habel, Renfeng Guo, Bruce P. Burnett, James Dickinson, Matthijs C. Brouwer, Niels C. Riedemann, Diederik van de Beek, the PANAMO study group

    Published 2023-06-01
    Get full text
    Article
  2. 2
    The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19

    The anti‐C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID‐19 by Alexander P. J. Vlaar, Endry H. T. Lim, Sanne deBruin, Simon Rückinger, Korinna Pilz, Matthijs C. Brouwer, Ren‐Feng Guo, Leo M. A. Heunks, Matthias H. Busch, Pieter vanPaassen, Niels C. Riedemann, Diederik van deBeek

    Published 2022-04-01
    Get full text
    Article
  3. 3
    Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany.

    Post-pandemic seroprevalence of pandemic influenza A (H1N1) 2009 infection (swine flu) among children <18 years in Germany. by Rüdiger von Kries, Susanne Weiss, Gerhard Falkenhorst, Stephan Wirth, Petra Kaiser, Hans-Iko Huppertz, Tobias Tenenbaum, Horst Schroten, Andrea Streng, Johannes Liese, Sonu Shai, Tim Niehues, Hermann Girschick, Ellen Kuscher, Axel Sauerbrey, Jochen Peters, Carl Heinz Wirsing von König, Simon Rückinger, Walter Hampl, Detlef Michel, Thomas Mertens

    Published 2011-01-01
    Get full text
    Article

Search Tools: